Table 2.
The association between co-expression of IDO/CD33 and clinicopathological features prior NCT.
| Clinicopathological features |
|
n |
IDO−CD33− |
IDO−CD33+ |
IDO+CD33− |
IDO+CD33+ |
x2 |
P |
| Total | 54 | 16 | 11 | 5 | 22 | |||
| Age | <50 | 26 | 7 | 8 | 1 | 10 | 4.437 | 0.218 |
| ≥50 | 28 | 9 | 3 | 4 | 12 | |||
| Menopausal status | Pre- | 28 | 9 | 4 | 4 | 11 | 2.798 | 0.424 |
| Post- | 26 | 7 | 7 | 2 | 10 | |||
| History of gravidity | No | 7 | 3 | 3 | 1 | 0 | 5.967 | 0.133 |
| Yes | 47 | 13 | 8 | 4 | 22 | |||
| Family history of maligant | No | 40 | 11 | 10 | 3 | 16 | 2.396 | 0.494 |
| Yes | 14 | 5 | 1 | 2 | 6 | |||
| Clinical T stage | T1, T2 | 23 | 14 | 3 | 2 | 4 | 19.627 | 0.000 |
| T3, T4 | 31 | 2 | 8 | 3 | 18 | |||
| Clinical N stage | N0 | 13 | 6 | 4 | 1 | 2 | 5.234 | 0.155 |
| N1-N3 | 41 | 10 | 7 | 4 | 20 | |||
| Clinical stage | I, II | 14 | 4 | 5 | 2 | 3 | 4.430 | 0.218 |
| III, IV | 40 | 12 | 6 | 3 | 19 | |||
| Histological type | IDBC | 44 | 13 | 10 | 4 | 17 | 0.914 | 0.822 |
| Other | 10 | 3 | 1 | 1 | 5 | |||
| ER | − | 24 | 7 | 9 | 2 | 6 | 8.893 | 0.031 |
| + | 30 | 9 | 2 | 3 | 16 | |||
| PR | − | 27 | 10 | 4 | 3 | 10 | 2.200 | 0.532 |
| + | 27 | 6 | 7 | 2 | 12 | |||
| Her-2 | − | 33 | 11 | 8 | 4 | 10 | 4.037 | 0.122 |
| + | 21 | 5 | 3 | 1 | 12 | |||
| Ki67 | − | 22 | 8 | 6 | 2 | 6 | 3.090 | 0.378 |
| + | 32 | 8 | 5 | 3 | 16 | |||
| P53 | − | 23 | 6 | 7 | 1 | 9 | 3.231 | 0.357 |
| + | 21 | 10 | 4 | 4 | 13 | |||
| Luminal type | Luminal | 42 | 12 | 7 | 4 | 19 | 8.921 | 0.178 |
| Her-2 | 4 | 1 | 3 | 0 | 0 | |||
| Basal-like | 8 | 3 | 1 | 1 | 3 |
IDBC: Invasive ductal breast cancer.